Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12188/26309
DC FieldValueLanguage
dc.contributor.authorPenshovska Nikolova, Veraen_US
dc.date.accessioned2023-04-11T07:46:21Z-
dc.date.available2023-04-11T07:46:21Z-
dc.date.issued2019-
dc.identifier.urihttp://hdl.handle.net/20.500.12188/26309-
dc.description.abstractBackground;Main hormons involved in regulation of glucose are glucagon like peptid GLP-1 and glucose dependent insulotropic polipeptid GIP .Both of them are inactivated by the enzim dipeptil peptidasa -4 (DPP-4) .Incretin based therapies include GLP -1 receptor agonist and DPP-4 inhibitors wich main actions are to increase secretion of insulin and inhibit secretion of glucagon . Objectives ; providing review of clinical trials of liraglutide-SGLT2 inhibitors cause an increase in HGP accompanied with an increase in plasma glucagon concentration .Increase in plasma glucagon concentration is partly responsible for the increase in HGP. The aim of study was to examine whether inhibition of glucagon secretion by liraglutide can prevent the increase in HGP. Research and methods ;51 T2DM patients(age=55+-1 year;45% female;BMI=35,6+-0,9;diabetes duration =7,8+-0,9 year;FPG=175+-7;HbA1=8,5+-0,1%) were randomized to receive for 14 weeks(i)metformin 1g ;(ii)liraglutide1,8 mg;or(iii)metformin 1g plus liraglutide1,8 mg. HGP(measured with 3-3H-glucose infusion) and plasma glucagon concentration were measured before and after 14 weeks of treatment. Results ;Metformin monotherapy caused a significant reduction in HbA1c(-1,1-+0,2%,p<0,01) accompanied with an increase in plasma glucagon concentration (by 28%,p<0,05)which lasted for 14 weeks. Liraglutide monoterapy caused a 1,6+-0,5%(p<0,01)reduction in HbA1C accompanied by a small(6 %) reduction in HGP (P=ns)without significant change in fasting plasma glucagon concentration. The combination of metformin plus liraglutide caused a greater reduction in HBa1c(1,9-+0,5%,p<0,05vs metformin and p=NS vs liraglutide)and attenuated the increase in fasting plasma glucagon and basal HGP at 14 weeks . Conclusion ;These results;1)support a possible role for increased plasma glucagon levels in the long term maintenance of increase in HGP caused by SGLT2i,and 2.)suggest that factors other than in addition to glucagon contribute to the initiation of the increase in HGPen_US
dc.language.isoenen_US
dc.titleSafety effect of combination therapy with Liraglutide plus metformin on HGP and HBA1C vs each therapy alone in patients with DM T2en_US
dc.typeProceeding articleen_US
dc.relation.conferenceThird EASD Incretin Study Group Meeting, 2019; Bohum, Germanyen_US
item.grantfulltextopen-
item.fulltextWith Fulltext-
Appears in Collections:Faculty of Medicine: Conference papers
Files in This Item:
File Description SizeFormat 
Bochum 2019.png192.87 kBimage/pngThumbnail
View/Open
EASD-isg2019_Program.pdf5.5 MBAdobe PDFView/Open
Show simple item record

Page view(s)

92
checked on Jul 18, 2024

Download(s)

36
checked on Jul 18, 2024

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.